EXPERT REACTION: Moderna vaccine reports 100% efficacy against severe COVID
Randomised controlled trial: Subjects are randomly assigned to a test group, which receives the treatment, or a control group, which commonly receives a placebo. In 'blind' trials, participants do not know which group they are in; in ‘double blind’ trials, the experimenters do not know either. Blinding trials helps removes bias.
People: This is a study based on research using people.
Overnight, Moderna has reported further results of their Phase 3 COVID vaccine study. The results, based on 30,000 participants, included 196 cases of COVID-19, of which 30 cases were severe. According to the company, the vaccine's efficacy was 94.1 per cent overall. The data also suggest the vaccine is 100 per cent effective against severe COVID-19. Moderna also announced it will request Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA), and apply for a conditional marketing authorisation with the European Medicines Agency (EMA).
Organisation/s: Moderna
Attachments:
Note: Not all attachments are visible to the general public
News for:
International
NSW
VIC
QLD
Media contact details for this story are only visible to registered journalists.
Expert Reaction
These comments have been collated by the Science Media Centre to provide a variety of expert perspectives on this issue. Feel free to use these quotes in your stories. Views expressed are the personal opinions of the experts named. They do not represent the views of the SMC or any other organisation unless specifically stated.